✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tremelimumab is an investigational drug.
There have been 173 clinical trials for Tremelimumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 21st 2015.
The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are AstraZeneca, MedImmune LLC, and National Cancer Institute (NCI).
There are ninety-four US patents protecting this investigational drug and one international patent.
Recent Clinical Trials for Tremelimumab
|Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)||AHS Cancer Control Alberta||Phase 2|
|Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer||AstraZeneca||Phase 2|
|Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer||Washington University School of Medicine||Phase 2|
Top disease conditions for Tremelimumab
Top clinical trial sponsors for Tremelimumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Tremelimumab||See Plans and Pricing||Immunoregulatory agents||Flexus Biosciences, Inc. (Princeton, NJ)||See Plans and Pricing|
|Tremelimumab||See Plans and Pricing||.beta.-glucan methods and compositions that affect the tumor microenvironment||BIOTHERA, INC. (Eagan, MN)||See Plans and Pricing|
|Tremelimumab||See Plans and Pricing||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Tremelimumab||Argentina||AR102536||2034-11-05||See Plans and Pricing|
|Tremelimumab||Australia||AU2015342940||2034-11-05||See Plans and Pricing|
|Tremelimumab||Brazil||BR112017008568||2034-11-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|